Holen Sie sich die Stockscreener-App
8.57
3.38%
-0.30
Schlusskurs vom Vortag:
$8.87
Offen:
$8.66
24-Stunden-Volumen:
2.21M
Relative Volume:
1.86
Marktkapitalisierung:
$520.00M
Einnahmen:
$65,400
Nettoeinkommen (Verlust:
$-46.34M
KGV:
-9.9651
EPS:
-0.86
Netto-Cashflow:
$-38.74M
1W Leistung:
+2.27%
1M Leistung:
-20.20%
6M Leistung:
+93.45%
1J Leistung:
+146.97%
1-Tages-Spanne:
$8.51
$8.95
1-Wochen-Bereich:
$8.0046
$9.02
52-Wochen-Spanne:
$2.89
$13.85
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Vergleichen Sie CRMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
8.57 | 520.00M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
CorMedix price target raised to $12 from $11 at RBC Capital - Yahoo Finance
RBC optimistic on CorMedix shares as DefenCath launch gains traction in outpatient - Investing.com Australia
CorMedix's SWOT analysis: defencath launch boosts stock amid expansion plans By Investing.com - Investing.com South Africa
CorMedix's SWOT analysis: defencath launch boosts stock amid expansion plans - Investing.com Australia
CorMedix Inc. Added to Nasdaq Biotechnology Index - The Manila Times
CorMedix joins Nasdaq Biotechnology Index - Investing.com
CorMedix (CRMD) Earns Coveted Spot in Nasdaq Biotechnology Index in December Update - StockTitan
Is CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? - Insider Monkey
CorMedix's SWOT analysis: defencath launch propels stock amid expansion - Investing.com
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark - Simply Wall St
CorMedix's SWOT analysis: defencath launch boosts stock outlook By Investing.com - Investing.com South Africa
CorMedix's SWOT analysis: defencath launch boosts stock outlook - Investing.com
Closed System Transfer Device Market Size Poised to Hit USD 4,753.71 million by 2034, Driven by a 14.1% CAGR | PMR - GlobeNewswire Inc.
When (CRMD) Moves Investors should Listen - Stock Traders Daily
CorMedix Inc. Announces FDA IND Filing for Neutrolin(R) in United States - Marketscreener.com
CorMedix supports CMS policy updates - TipRanks
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products - The Manila Times
CorMedix: Major CMS Policy Change to Boost DefenCath Access for 30% of Dialysis Patients | CRMD Stock News - StockTitan
CorMedix Approves Key Governance and Incentive Changes - TipRanks
Cormedix EVP Elizabeth Hurlburt sells $1.57m in stock - Investing.com India
When the Price of (CRMD) Talks, People Listen - Stock Traders Daily
Nomura Holdings Inc's Strategic Reduction in CorMedix Inc Shares - GuruFocus.com
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns - Simply Wall St
CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Best Momentum Stocks To Buy For November 8th - Barchart
Best Momentum Stocks to Buy for November 8th - Yahoo Finance
Trend Tracker for (CRMD) - Stock Traders Daily
Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High? - Yahoo Finance
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium - The Manila Times
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts - Simply Wall St
Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic - Yahoo Finance UK
CorMedix: Q3 Earnings Snapshot - AOL
While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate - Yahoo Finance
Recent 23% pullback isn't enough to hurt long-term CorMedix (NASDAQ:CRMD) shareholders, they're still up 188% over 1 year - Simply Wall St
CorMedix Inc. (NASDAQ:CRMD) Q3 2024 Earnings Call Transcript - Insider Monkey
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates - MSN
CorMedix Inc. Reports Q3 2024 Financial Results - TipRanks
CorMedix (CRMD) Q3 2024 Earnings Call Transcript - The Motley Fool
Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth By Investing.com - Investing.com South Africa
Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth - Investing.com India
CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):